- Home
- INZY vs RDCM Comparison
INZY vs RDCM Comparison
Compare INZY & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- RDCM
- Stock Information
- Founded
- INZY 2015
- RDCM 1985
- Country
- INZY United States
- RDCM Israel
- Employees
- INZY N/A
- RDCM N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- RDCM Computer peripheral equipment
- Sector
- INZY Health Care
- RDCM Technology
- Exchange
- INZY Nasdaq
- RDCM Nasdaq
- Market Cap
- INZY 188.2M
- RDCM 157.9M
- IPO Year
- INZY 2020
- RDCM 1997
- Fundamental
- Price
- INZY $1.36
- RDCM $14.08
- Analyst Decision
- INZY Strong Buy
- RDCM Strong Buy
- Analyst Count
- INZY 8
- RDCM 2
- Target Price
- INZY $17.75
- RDCM $15.00
- AVG Volume (30 Days)
- INZY 784.0K
- RDCM 71.7K
- Earning Date
- INZY 03-11-2025
- RDCM 02-12-2025
- Dividend Yield
- INZY N/A
- RDCM N/A
- EPS Growth
- INZY N/A
- RDCM 660.55
- EPS
- INZY N/A
- RDCM 0.46
- Revenue
- INZY N/A
- RDCM $58,755,000.00
- Revenue This Year
- INZY N/A
- RDCM $18.92
- Revenue Next Year
- INZY N/A
- RDCM $11.27
- P/E Ratio
- INZY N/A
- RDCM $30.30
- Revenue Growth
- INZY N/A
- RDCM 17.80
- 52 Week Low
- INZY $1.32
- RDCM $8.18
- 52 Week High
- INZY $7.80
- RDCM $14.33
- Technical
- Relative Strength Index (RSI)
- INZY 20.27
- RDCM 67.92
- Support Level
- INZY $1.32
- RDCM $11.90
- Resistance Level
- INZY $3.18
- RDCM $13.37
- Average True Range (ATR)
- INZY 0.27
- RDCM 0.77
- MACD
- INZY -0.15
- RDCM 0.19
- Stochastic Oscillator
- INZY 2.15
- RDCM 90.83
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.